menu
    • menu
    [{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Termination","leadProduct":"Fampridine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Acorda Therapeutics","amount2":0.51000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.51000000000000001,"dosageForm":"Prolonged Release Tablet","sponsorNew":"Acorda Therapeutics \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Acorda Therapeutics \/ Biogen"}]

    Find Clinical Drug Pipeline Developments & Deals for Dalfampridine

    Menu

    Dalfampridine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Acorda Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Acorda Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fampridine

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Biogen

                            Deal Size : $510.0 million

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025

                            Details : Following termination, Acorda regains global commercialization rights to Fampyra, a prolonged-release formulation of fampridine (4-aminopyridine) for adults with multiple sclerosis.

                            Brand Name : Fampyra

                            Molecule Type : Small molecule

                            Upfront Cash : $110.0 million

                            January 11, 2024

                            Lead Product(s) : Fampridine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Biogen

                            Deal Size : $510.0 million

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth